AI-driven pathology platforms unveiled by Tempus and HKUST advance cancer diagnostics

Tempus showcased how minimal residual disease (MRD) data can be leveraged across the cancer care continuum, emphasizing its AI-enabled platform partnered with Bristol Myers Squibb to enhance precision oncology and treatment‑response monitoring.

Separately, the Hong Kong University of Science and Technology introduced a novel pathology AI system that requires no fine‑tuning, aiming to streamline slide scanning, image quality control, and diagnostic workflows. Both initiatives highlight rapid advances in artificial‑intelligence tools for cancer detection, monitoring and research.